A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

NCT07217067 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: PKN605
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals